QianJin Pharmaceutical(SH:600479) Shang Hai Zheng Quan Bao·2025-09-17 20:33Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., is proceeding with the acquisition of stakes in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment, following the approval from the China Securities Regulatory Commission [1][2]. Group 1: Transaction Implementation - The transfer of ownership for the targeted assets has been completed, with the company acquiring 28.92% of Qianjin Xiangjiang Pharmaceutical and 68.00% of Qianjin Xieli Pharmaceutical [2]. - The involved parties, including Zhuzhou State-owned Assets Investment Holding Group Co., Ltd. and other individuals, have successfully transferred their shares to the company [2]. Group 2: Subsequent Matters - The company is required to issue shares and make cash payments to the relevant parties as per the transaction agreement, and must also handle the registration and listing of the newly issued shares [3]. - Changes related to the increase in registered capital and amendments to the company’s articles of association must be filed with the relevant regulatory authorities [3]. - The company must continue to fulfill its information disclosure obligations regarding the transaction as per legal and regulatory requirements [3]. Group 3: Independent Advisors' Opinions - The independent financial advisor, Guotou Securities Co., Ltd., confirmed that the transaction followed necessary decision-making and approval processes, and that the transfer of assets was legally valid [4][5]. - The legal advisor, Hunan Qiyuan Law Firm, stated that the transaction complies with legal regulations and that all necessary approvals have been obtained, ensuring that the company legally holds the assets [5].